foscarnet has been researched along with Viremia in 31 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
Viremia: The presence of viruses in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A randomized open-label phase 2 trial compared the virological and clinical effects on cytomegalovirus (CMV) infection of a 14-day course of intravenous foscarnet (100 mg/[kg x 12 h]) or no treatment in 42 HIV-infected patients with < 100 CD4 cells/mm3 and persistent asymptomatic CMV viremia." | 9.09 | Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study Group. ( Aboulker, JP; Brun-Vézinet, F; Carrière, I; Fillet, AM; Gérard, L; Houhou, N; Leport, C; Ostinelli, J; Salmon-Céron, D; Vildé, JL, 1999) |
| "Ganciclovir (GCV) and foscarnet (FOS) are the most commonly used antivirals for preemptive treatment of cytomegalovirus (CMV) viremia in recipients of allogeneic hematopoietic cell transplantation (alloHCT)." | 7.96 | Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia. ( Abella Ross, J; Al Malki, MM; Chen, J; Dadwal, SS; Dickter, JK; Ito, JI; Kriengkauykiat, J; Mokhtari, S; Nakamura, R; Tegtmeier, B; Yang, D; Zaia, JA, 2020) |
| "This single-center, retrospective study included immunosuppressed adults with CMV viremia who received foscarnet between January 2012-July 2017." | 7.91 | Recommended foscarnet dose is not associated with improved outcomes in cytomegalovirus salvage therapy. ( Athans, V; Koval, CE; Lam, SW; Spinner, ML, 2019) |
| " Immunosuppressive therapy was reduced, and the patient was treated with foscarnet for 2 weeks, leading to a dramatic normalization of blood cell counts, concomitantly with the disappearance of HHV-8 viremia." | 7.71 | Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet. ( Barozzi, P; Facchetti, F; Luppi, M; Rasini, V; Re, A; Riva, G; Rossi, G; Sandrini, S; Setti, G; Torelli, G, 2002) |
| " In this report we describe the effects of foscarnet on HHV-8 viremia in an HIV-infected patient with disseminated Kaposi s sarcoma and a presumably HHV-8 associated hemophagocytic syndrome." | 7.70 | Suppression of HHV-8 viremia by foscarnet in an HIV-infected patient with Kaposi's sarcoma and HHV-8 associated hemophagocytic syndrome. ( Fleckenstein, B; Harrer, T; Kalden, JR; Löw, P; Manger, B; Neipel, F; Rascu, A; Steininger, H, 1998) |
| "Foscarnet-resistant cytomegalovirus (ID50 > 300 microM) was isolated from two patients, one of whom was being treated with foscarnet." | 7.69 | Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir. ( Apuzzo, L; Charache, P; Dunn, JP; Forman, MS; Jabs, DA; MacCumber, MW, 1995) |
| "Cytomegalovirus (CMV) infection is still a problem for organ transplant recipients despite studies that long-term prophylaxis with high dose of acyclovir or ganciclovir given to all organ recipients may limit the consequences of infection and disease." | 7.69 | Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. ( Baruzzo, S; Gotti, E; Moioli, F; Perani, V; Remuzzi, G; Suter, F, 1996) |
| "In this phase 3, open-label study, hematopoietic-cell and solid-organ transplant recipients with R/R cytomegalovirus were randomized 2:1 to maribavir 400 mg twice daily or investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, or cidofovir) for 8 weeks, with 12 weeks of follow-up." | 5.51 | Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. ( Alain, S; Alexander, BD; Avery, RK; Blumberg, EA; Chemaly, RF; Cordonnier, C; Duarte, RF; Florescu, DF; Fournier, M; Kamar, N; Kumar, D; Maertens, J; Marty, FM; Papanicolaou, GA; Silveira, FP; Sundberg, AK; Witzke, O; Wu, J, 2022) |
| "A randomized open-label phase 2 trial compared the virological and clinical effects on cytomegalovirus (CMV) infection of a 14-day course of intravenous foscarnet (100 mg/[kg x 12 h]) or no treatment in 42 HIV-infected patients with < 100 CD4 cells/mm3 and persistent asymptomatic CMV viremia." | 5.09 | Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study Group. ( Aboulker, JP; Brun-Vézinet, F; Carrière, I; Fillet, AM; Gérard, L; Houhou, N; Leport, C; Ostinelli, J; Salmon-Céron, D; Vildé, JL, 1999) |
| "Ganciclovir (GCV) and foscarnet (FOS) are the most commonly used antivirals for preemptive treatment of cytomegalovirus (CMV) viremia in recipients of allogeneic hematopoietic cell transplantation (alloHCT)." | 3.96 | Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia. ( Abella Ross, J; Al Malki, MM; Chen, J; Dadwal, SS; Dickter, JK; Ito, JI; Kriengkauykiat, J; Mokhtari, S; Nakamura, R; Tegtmeier, B; Yang, D; Zaia, JA, 2020) |
| "This single-center, retrospective study included immunosuppressed adults with CMV viremia who received foscarnet between January 2012-July 2017." | 3.91 | Recommended foscarnet dose is not associated with improved outcomes in cytomegalovirus salvage therapy. ( Athans, V; Koval, CE; Lam, SW; Spinner, ML, 2019) |
| " Immunosuppressive therapy was reduced, and the patient was treated with foscarnet for 2 weeks, leading to a dramatic normalization of blood cell counts, concomitantly with the disappearance of HHV-8 viremia." | 3.71 | Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet. ( Barozzi, P; Facchetti, F; Luppi, M; Rasini, V; Re, A; Riva, G; Rossi, G; Sandrini, S; Setti, G; Torelli, G, 2002) |
| "Seventeen AIDS patients with cytomegalovirus (CMV), herpes simplex virus (HSV), varicella-zoster virus (VZV) infection, Kaposi's sarcoma (KS), or a combination of these were treated with foscarnet." | 3.70 | Foscarnet decreases HIV-1 plasma load. ( Barbeau, P; Breilh, D; Denisi, R; Devianne-Garrigue, I; Dupon, M; Fleury, HJ; Leng, B; Pellegrin, I; Pellegrin, JL; Ragnaud, JM, 1998) |
| " In this report we describe the effects of foscarnet on HHV-8 viremia in an HIV-infected patient with disseminated Kaposi s sarcoma and a presumably HHV-8 associated hemophagocytic syndrome." | 3.70 | Suppression of HHV-8 viremia by foscarnet in an HIV-infected patient with Kaposi's sarcoma and HHV-8 associated hemophagocytic syndrome. ( Fleckenstein, B; Harrer, T; Kalden, JR; Löw, P; Manger, B; Neipel, F; Rascu, A; Steininger, H, 1998) |
| "Foscarnet-resistant cytomegalovirus (ID50 > 300 microM) was isolated from two patients, one of whom was being treated with foscarnet." | 3.69 | Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir. ( Apuzzo, L; Charache, P; Dunn, JP; Forman, MS; Jabs, DA; MacCumber, MW, 1995) |
| " The first developed three episodes of cytomegaloviremia requiring anti-viral therapy; the third episode accompanied by cytomegalovirus hepatitis which required prolonged therapy with foscarnet." | 3.69 | Unusual infections following allogeneic bone marrow transplantation for chronic lymphocytic leukemia. ( Brincat, S; Catovsky, D; Iveson, T; Jameson, B; Mehta, J; Paul, B; Powles, R; Singhal, S; Treleaven, J; Zomas, A, 1994) |
| "To determine the prevalence of cytomegalovirus (CMV) isolates resistant to ganciclovir sodium or foscarnet sodium at the time of diagnosis of CMV retinitis, prior to the initiation of therapy." | 3.69 | Cytomegalovirus retinitis and viral resistance. Prevalence of resistance at diagnosis, 1994. Cytomegalovirus Retinitis and Viral Resistance Study Group. ( Bressler, N; Charache, P; Dunn, JP; Enger, C; Forman, M; Jabs, DA, 1996) |
| "Cytomegalovirus (CMV) infection is still a problem for organ transplant recipients despite studies that long-term prophylaxis with high dose of acyclovir or ganciclovir given to all organ recipients may limit the consequences of infection and disease." | 3.69 | Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. ( Baruzzo, S; Gotti, E; Moioli, F; Perani, V; Remuzzi, G; Suter, F, 1996) |
| " Cytomegalovirus prophylaxis consisted of acyclovir for SIBs and foscarnet for MUDs." | 3.69 | Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience. ( Bacigalupo, A; Barbanti, M; Corvo, R; Delfino, L; Ferrara, GB; Ficai, G; Frassoni, F; Ghinatti, C; Gualandi, F; Lamparelli, T; Morabito, A; Occhini, D; Pozzi, S; Sacchi, N; Van Lint, MT; Vitale, V; Zikos, P, 1997) |
| " Grade 3 or greater adverse events occurred in 9 of the 10 prophylactic PFA patients and in 7 of the 10 control patients who had clinical backgrounds similar to the study subjects and underwent SCT during the same period." | 2.77 | Safety of pre-engraftment prophylactic foscarnet administration after allogeneic stem cell transplantation. ( Hosokawa, K; Ishiyama, K; Katagiri, T; Kondo, Y; Nakao, S; Ohata, K; Takami, A; Yamazaki, H, 2012) |
| "However, it may develop in patients with acute lymphoblastic leukemia (ALL) who have not undergone hematopoietic cell transplantation." | 2.53 | Cytomegalovirus Retinitis in Three Pediatric Cases with Acute Lymphoblastic Leukemia: Case Series and Review of the Literature. ( Akkoç, G; Atıcı, S; Bakır, M; Çeliker, H; Demir, SÖ; Kadayifci, EK; Karaaslan, A; Kazokoğlu, H; Koç, A; Şenay, E; Soysal, A; Yakut, N, 2016) |
| "Foscarnet was restarted and continued until day +269 UCBT due to multiple HHV-6 recurrences with persistent hyponatremia." | 1.91 | Human herpesvirus 6 (HHV-6) associated permanent hyponatremia in umbilical cord blood transplant recipient. ( Gannamani, V; Nathan, S; Ustun, C; Varma, A, 2023) |
| " Continued induction dosing or re-induction may protect against early breakthrough CMV disease and CMV-related death among patients with rising antigenemia on preemptive therapy." | 1.31 | Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. ( Boeckh, M; Corey, L; Davis, C; Drew, WL; Gooley, T; Huang, M; Miner, R; Nichols, WG, 2001) |
| "CMV viremia was present in 4 patients." | 1.29 | Cytomegalovirus ventriculoencephalitis in AIDS patients. ( Fernandez-Viladrich, P; Ferrer, I; Gudiol, F; Perez, JL; Podzamczer, D; Reñe, R; Salazar, A; Santin, M, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (48.39) | 18.2507 |
| 2000's | 6 (19.35) | 29.6817 |
| 2010's | 7 (22.58) | 24.3611 |
| 2020's | 3 (9.68) | 2.80 |
| Authors | Studies |
|---|---|
| Avery, RK | 1 |
| Alain, S | 1 |
| Alexander, BD | 1 |
| Blumberg, EA | 1 |
| Chemaly, RF | 1 |
| Cordonnier, C | 1 |
| Duarte, RF | 1 |
| Florescu, DF | 1 |
| Kamar, N | 1 |
| Kumar, D | 1 |
| Maertens, J | 1 |
| Marty, FM | 1 |
| Papanicolaou, GA | 1 |
| Silveira, FP | 2 |
| Witzke, O | 1 |
| Wu, J | 1 |
| Sundberg, AK | 1 |
| Fournier, M | 1 |
| Gannamani, V | 1 |
| Varma, A | 1 |
| Nathan, S | 1 |
| Ustun, C | 1 |
| Spinner, ML | 1 |
| Lam, SW | 1 |
| Koval, CE | 1 |
| Athans, V | 1 |
| Chen, J | 1 |
| Abella Ross, J | 1 |
| Tegtmeier, B | 1 |
| Yang, D | 1 |
| Ito, JI | 1 |
| Zaia, JA | 1 |
| Dickter, JK | 1 |
| Nakamura, R | 1 |
| Mokhtari, S | 1 |
| Kriengkauykiat, J | 1 |
| Al Malki, MM | 1 |
| Dadwal, SS | 1 |
| Wieruszewski, PM | 1 |
| Vijayvargiya, P | 1 |
| Wilhelm, MP | 1 |
| Razonable, RR | 1 |
| Vora, SB | 1 |
| Brothers, AW | 1 |
| Waghmare, A | 1 |
| Englund, JA | 1 |
| Minces, LR | 1 |
| Nguyen, MH | 1 |
| Mitsani, D | 1 |
| Shields, RK | 1 |
| Kwak, EJ | 1 |
| Abdel-Massih, R | 1 |
| Pilewski, JM | 1 |
| Crespo, MM | 1 |
| Bermudez, C | 1 |
| Bhama, JK | 1 |
| Toyoda, Y | 1 |
| Clancy, CJ | 1 |
| Demir, SÖ | 1 |
| Çeliker, H | 1 |
| Karaaslan, A | 1 |
| Kadayifci, EK | 1 |
| Akkoç, G | 1 |
| Atıcı, S | 1 |
| Yakut, N | 1 |
| Şenay, E | 1 |
| Kazokoğlu, H | 1 |
| Koç, A | 1 |
| Bakır, M | 1 |
| Soysal, A | 1 |
| Ambrose, T | 1 |
| Sharkey, LM | 1 |
| Louis-Auguste, J | 1 |
| Rutter, CS | 1 |
| Duncan, S | 1 |
| English, S | 1 |
| Gkrania-Klotsas, E | 1 |
| Carmichael, A | 1 |
| Woodward, JM | 1 |
| Russell, N | 1 |
| Massey, D | 1 |
| Butler, A | 1 |
| Middleton, S | 1 |
| Wang, H | 1 |
| Zhu, L | 1 |
| Xue, M | 1 |
| Liu, J | 1 |
| Guo, Z | 1 |
| Ishiyama, K | 1 |
| Katagiri, T | 1 |
| Ohata, K | 1 |
| Hosokawa, K | 1 |
| Kondo, Y | 1 |
| Yamazaki, H | 1 |
| Takami, A | 1 |
| Nakao, S | 1 |
| Luppi, M | 1 |
| Barozzi, P | 1 |
| Rasini, V | 1 |
| Riva, G | 1 |
| Re, A | 1 |
| Rossi, G | 1 |
| Setti, G | 1 |
| Sandrini, S | 1 |
| Facchetti, F | 1 |
| Torelli, G | 1 |
| Salazar, A | 1 |
| Podzamczer, D | 1 |
| Reñe, R | 1 |
| Santin, M | 1 |
| Perez, JL | 1 |
| Ferrer, I | 1 |
| Fernandez-Viladrich, P | 1 |
| Gudiol, F | 1 |
| Dunn, JP | 3 |
| MacCumber, MW | 1 |
| Forman, MS | 1 |
| Charache, P | 2 |
| Apuzzo, L | 1 |
| Jabs, DA | 3 |
| Zomas, A | 1 |
| Mehta, J | 1 |
| Powles, R | 1 |
| Treleaven, J | 1 |
| Iveson, T | 1 |
| Singhal, S | 1 |
| Jameson, B | 1 |
| Paul, B | 1 |
| Brincat, S | 1 |
| Catovsky, D | 1 |
| Drobyski, WR | 1 |
| Dunne, WM | 1 |
| Burd, EM | 1 |
| Knox, KK | 1 |
| Ash, RC | 1 |
| Horowitz, MM | 1 |
| Flomenberg, N | 1 |
| Carrigan, DR | 1 |
| Enger, C | 2 |
| Forman, M | 2 |
| Bressler, N | 1 |
| Ljungman, P | 1 |
| Loré, K | 1 |
| Aschan, J | 1 |
| Klaesson, S | 1 |
| Lewensohn-Fuchs, I | 1 |
| Lönnqvist, B | 1 |
| Ringdén, O | 1 |
| Winiarski, J | 1 |
| Ehrnst, A | 1 |
| Gotti, E | 1 |
| Suter, F | 1 |
| Baruzzo, S | 1 |
| Perani, V | 1 |
| Moioli, F | 1 |
| Remuzzi, G | 1 |
| Lamparelli, T | 1 |
| Van Lint, MT | 1 |
| Gualandi, F | 1 |
| Occhini, D | 1 |
| Barbanti, M | 1 |
| Sacchi, N | 1 |
| Ficai, G | 1 |
| Ghinatti, C | 1 |
| Ferrara, GB | 1 |
| Delfino, L | 1 |
| Pozzi, S | 1 |
| Morabito, A | 1 |
| Zikos, P | 1 |
| Vitale, V | 1 |
| Corvo, R | 1 |
| Frassoni, F | 1 |
| Bacigalupo, A | 1 |
| Devianne-Garrigue, I | 1 |
| Pellegrin, I | 1 |
| Denisi, R | 1 |
| Dupon, M | 1 |
| Ragnaud, JM | 1 |
| Barbeau, P | 1 |
| Breilh, D | 1 |
| Leng, B | 1 |
| Fleury, HJ | 1 |
| Pellegrin, JL | 1 |
| Löw, P | 1 |
| Neipel, F | 1 |
| Rascu, A | 1 |
| Steininger, H | 1 |
| Manger, B | 1 |
| Fleckenstein, B | 1 |
| Kalden, JR | 1 |
| Harrer, T | 1 |
| Hubbard, L | 1 |
| Baldanti, F | 1 |
| Revello, MG | 1 |
| Percivalle, E | 1 |
| Gerna, G | 1 |
| Stocchi, R | 1 |
| Ward, KN | 1 |
| Fanin, R | 1 |
| Baccarani, M | 1 |
| Apperley, JF | 1 |
| Boivin, G | 1 |
| Handfield, J | 1 |
| Toma, E | 1 |
| Lalonde, R | 1 |
| Bergeron, MG | 1 |
| Salmon-Céron, D | 1 |
| Fillet, AM | 1 |
| Aboulker, JP | 1 |
| Gérard, L | 1 |
| Houhou, N | 1 |
| Carrière, I | 1 |
| Ostinelli, J | 1 |
| Vildé, JL | 1 |
| Brun-Vézinet, F | 1 |
| Leport, C | 1 |
| Nichols, WG | 1 |
| Corey, L | 1 |
| Gooley, T | 1 |
| Drew, WL | 1 |
| Miner, R | 1 |
| Huang, M | 1 |
| Davis, C | 1 |
| Boeckh, M | 1 |
| Kiehl, MG | 1 |
| Basara, N | 1 |
| Castagnola, E | 1 |
| Miano, M | 1 |
| Morreale, G | 1 |
| Cristina, E | 1 |
| Chierici, M | 1 |
| Lanino, E | 1 |
| Chakrabarti, S | 1 |
| Collingham, KE | 1 |
| Osman, H | 1 |
| Fegan, CD | 1 |
| Milligan, DW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory[NCT02931539] | Phase 3 | 352 participants (Actual) | Interventional | 2016-12-22 | Completed | ||
| Phase II, Multicentric, Prospective and Opened Clinical Trial of Advance Valganciclovir Treatment of CMV in Allogenic Hematopoietic Progenitors Transplant[NCT00386412] | Phase 2 | 132 participants (Anticipated) | Interventional | 2005-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
All-cause mortality was analyzed by the end of study regardless of the use of rescue treatment or alternative anti-CMV treatment. Number of participants who died during the entire study period were reported. (NCT02931539)
Timeframe: From enrollment up to end of study (approximately 44 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 13 |
| Maribavir 400 mg | 27 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration
Timeframe: Up to Week 16
| Intervention | percentage of participants (Number) |
|---|---|
| Maribavir Rescue Arm | 27.3 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration
Timeframe: From start of maribavir rescue treatment through 8 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Maribavir Rescue Arm | 50.0 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration less than (<) lower limit of quantification (LLOQ) that is, <137 International Units per milliliter (IU/mL) when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive postbaseline samples, separated by at least 5 days. Percentage of participants with confirmed CMV viremia clearance at end of study Week 8 regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy, and could not have received alternative anti-CMV treatment were reported. (NCT02931539)
Timeframe: Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 23.9 |
| Maribavir 400 mg | 55.7 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration
Timeframe: Up to Week 16
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 10.3 |
| Maribavir 400 mg | 18.7 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants who completed 8 weeks of study-assigned treatment with recurrence of CMV viremia during the 12 weeks of follow-up period were reported. (NCT02931539)
Timeframe: End of Week 8 up to Week 20 (12 weeks follow-up period)
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 35.5 |
| Maribavir 400 mg | 40.9 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants with Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants who completed 8 weeks of study-assigned treatment with recurrence of CMV viremia during the 20 weeks of study were reported. (NCT02931539)
Timeframe: Baseline up to Week 20
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 45.2 |
| Maribavir 400 mg | 56.1 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants with recurrence of CMV viremia during the first 8 Weeks of the treatment who completed 8 weeks of study-assigned treatment were reported. (NCT02931539)
Timeframe: Baseline up to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 9.7 |
| Maribavir 400 mg | 15.2 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance, regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy. Percentage of participants with recurrence of CMV viremia during at any time on study regardless of whether study-assigned treatment was discontinued before 8 weeks of therapy were reported. (NCT02931539)
Timeframe: Baseline up to Week 20
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 33.8 |
| Maribavir 400 mg | 56.5 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance, regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy. Percentage of participants with recurrence of CMV viremia during the 12 weeks follow-up period regardless of whether study-assigned treatment was discontinued before 8 weeks of therapy were reported. (NCT02931539)
Timeframe: End of Week 8 up to Week 20 (12 weeks follow-up period)
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 21.5 |
| Maribavir 400 mg | 38.6 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration greater than or equal to (>=) LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance, regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy. Percentage of participants with recurrence of CMV viremia during the first 8 weeks of study regardless of whether study-assigned treatment was discontinued before 8 weeks of therapy were reported. (NCT02931539)
Timeframe: At Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 12.3 |
| Maribavir 400 mg | 17.9 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants with recurrence of CMV viremia while off study-assigned treatment during follow-up period were reported. (NCT02931539)
Timeframe: Termination of study treatment (Week 8) up to the End of the Study (Week 20)
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 29.2 |
| Maribavir 400 mg | 40.8 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants with recurrence of CMV viremia while on study-assigned treatment period were reported. (NCT02931539)
Timeframe: Baseline up to termination of study treatment (up to Week 8)
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 4.6 |
| Maribavir 400 mg | 15.8 |
The time to all-cause mortality by the end of the study participation in days was calculated. Participants who were alive at the last study follow-up (regardless of use of rescue or alternative anti-CMV treatment), withdrew from study or were lost to follow-up were censored at the date of last contact. (NCT02931539)
Timeframe: From enrollment to last serious adverse event (SAE) follow-up (approximately Week 28)
| Intervention | days (Median) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 73.0 |
| Maribavir 400 mg | 55.0 |
Resistance-associated amino acid substitutions (RASs) to maribavir are known to generally map to the pUL97 and pUL27 genes. Genotyping was performed to identify RASs mapping to the pUL97 and pUL27 genes. Number of participants who had maribavir CMV resistance at baseline were reported. (NCT02931539)
Timeframe: At Baseline
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| RASs associated with pUL97 only | RASs associated with pUL27 only | RASs associated with pUL97 and pUL27 | |
| Investigator-assigned Anti-CMV Treatment (IAT) | 3 | 0 | 0 |
| Maribavir 400 mg | 0 | 1 | 0 |
| Maribavir Rescue Arm | 1 | 0 | 0 |
Resistance-associated amino acid substitutions (RASs) to maribavir are known to generally map to the pUL97 and pUL27 genes. Genotyping was performed to identify RASs mapping to the pUL97 and pUL27 genes. Number of participants who had post-baseline resistance to maribavir were reported. (NCT02931539)
Timeframe: After first dose of study drug up to Week 20
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| RASs associated with pUL97 only | RASs associated with pUL27 only | RASs associated with pUL97 and pUL27 | |
| Investigator-assigned Anti-CMV Treatment (IAT) | 0 | 0 | 0 |
| Maribavir 400 mg | 45 | 0 | 0 |
| Maribavir Rescue Arm | 4 | 0 | 0 |
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. Serious AE was any untoward medical occurrence (whether considered to be related to study-assigned treatment or not) that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital abnormality/birth defect, or was an important medical event. TEAEs was defined as any adverse events (classified by preferred term) that had a start date on or after the first dose of study treatment or that had a start date before the date of first dose of study treatment, but increased in severity after the first dose of study treatment. (NCT02931539)
Timeframe: Baseline up to 7 days or 21 days (if cidofovir used) after the last dose of study treatment (up to Week 8)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| TEAEs | Serious TEAEs | |
| Investigator-assigned Anti-CMV Treatment (IAT) | 106 | 43 |
| Maribavir 400 mg | 228 | 90 |
| Maribavir Rescue Arm | 22 | 11 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration
Timeframe: At Week 8 through Weeks 12, 16 and 20
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| At Week 8 | At Week 12 | At Week 16 | At Week 20 | |
| Investigator-assigned Anti-CMV Treatment (IAT) | 18.8 | 5.1 | 5.1 | 4.3 |
| Maribavir 400 mg | 54.9 | 22.6 | 18.7 | 18.3 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration
Timeframe: At Week 8 through Weeks 12, 16 and 20
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| At Week 8 | At Week 12 | At Week 16 | At Week 20 | |
| Investigator-assigned Anti-CMV Treatment (IAT) | 18.8 | 5.1 | 5.1 | 4.3 |
| Maribavir 400 mg | 54.9 | 22.6 | 18.7 | 18.3 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration
Timeframe: At Week 8 through Weeks 12 and 20
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| At Week 8 | At Week 12 | At Week 20 | |
| Investigator-assigned Anti-CMV Treatment (IAT) | 23.9 | 10.3 | 9.4 |
| Maribavir 400 mg | 55.7 | 22.6 | 18.3 |
Cmin of maribavir was reported. (NCT02931539)
Timeframe: Predose at Week 1, 4 and 8
| Intervention | micrograms per milliliter (mcg/mL) (Mean) | ||
|---|---|---|---|
| Cmin at Week 1 | Cmin at Week 4 | Cmin at Week 8 | |
| Maribavir 400 mg | 8.77 | 7.59 | 7.19 |
| Maribavir Rescue Arm | 8.57 | 5.75 | 5.65 |
3 reviews available for foscarnet and Viremia
| Article | Year |
|---|---|
Cytomegalovirus Retinitis in Three Pediatric Cases with Acute Lymphoblastic Leukemia: Case Series and Review of the Literature.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Antiviral Agents; Child; Child, Presc | 2016 |
Use of the human cytomegalovirus (HCMV) antigenemia assay for diagnosis and monitoring of HCMV infections and detection of antiviral drug resistance in the immunocompromised.
Topics: Antigens, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Drug Res | 1998 |
Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
Topics: Acyclovir; Adolescent; Adult; Antigens, Viral; Antiviral Agents; Bone Marrow Transplantation; Child; | 1999 |
5 trials available for foscarnet and Viremia
| Article | Year |
|---|---|
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Dichlororibofuranosylbenzimidazole; D | 2022 |
Safety of pre-engraftment prophylactic foscarnet administration after allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Antiviral Agents; DNA, Viral; Encephalitis, Viral; Female; Foscarnet; Hematopoiet | 2012 |
Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.
Topics: Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; DNA, Vir | 1996 |
Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study Group.
Topics: AIDS-Related Opportunistic Infections; Antigens, Viral; Antiviral Agents; Biomarkers; Cytomegaloviru | 1999 |
Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 2001 |
23 other studies available for foscarnet and Viremia
| Article | Year |
|---|---|
Human herpesvirus 6 (HHV-6) associated permanent hyponatremia in umbilical cord blood transplant recipient.
Topics: Cord Blood Stem Cell Transplantation; Female; Foscarnet; Herpesvirus 6, Human; Humans; Hyponatremia; | 2023 |
Recommended foscarnet dose is not associated with improved outcomes in cytomegalovirus salvage therapy.
Topics: Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Dosage Calculations; Fema | 2019 |
Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Chemoprevention; Child; Costs and Cost Analysis; Cytomega | 2020 |
Cytomegaloviraemia clearance with foscarnet during renal replacement therapy.
Topics: Aged; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Hemofiltration; Humans; Male; Renal D | 2018 |
Antiviral combination therapy for cytomegalovirus infection in high-risk infants.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Therapy, Combination; Female; Fo | 2018 |
Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.
Topics: Adult; Aged; Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Viral; Female; Foscarnet | 2014 |
Cytomegalovirus Infection and Rates of Antiviral Resistance Following Intestinal and Multivisceral Transplantation.
Topics: Adult; Aged; Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Viral; Female; Foscarnet | 2016 |
Low-dose foscarnet preemptive therapy for cytomegalovirus viremia after haploidentical bone marrow transplantation.
Topics: Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Female; | 2009 |
Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet.
Topics: Antiviral Agents; DNA, Viral; Foscarnet; Herpesvirus 8, Human; Humans; Kidney Transplantation; Male; | 2002 |
Cytomegalovirus ventriculoencephalitis in AIDS patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Autopsy; Brain; Cerebral Ventricles; Cerebrospinal Flu | 1995 |
Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus; Cytomegalovirus Retinitis; Disease Pr | 1995 |
Unusual infections following allogeneic bone marrow transplantation for chronic lymphocytic leukemia.
Topics: Adult; Anti-Bacterial Agents; Bone Marrow Transplantation; Cytomegalovirus Infections; Drug Therapy, | 1994 |
Human herpesvirus-6 (HHV-6) infection in allogeneic bone marrow transplant recipients: evidence of a marrow-suppressive role for HHV-6 in vivo.
Topics: Adult; Base Sequence; Bone Marrow; Bone Marrow Transplantation; Cohort Studies; Colony-Forming Units | 1993 |
Cytomegalovirus retinitis and viral resistance. Prevalence of resistance at diagnosis, 1994. Cytomegalovirus Retinitis and Viral Resistance Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Baltimore; Cytomegalovirus; Cytomega | 1996 |
Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
Topics: Adolescent; Adult; Antigens, Viral; Antiviral Agents; Chemoprevention; Child; Cytomegalovirus; Cytom | 1996 |
Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
Topics: Acyclovir; Adolescent; Adult; Antigens, Viral; Antiviral Agents; Bone Marrow Transplantation; Cause | 1997 |
Foscarnet decreases HIV-1 plasma load.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antiviral Agents; Cytomegalovirus Infections; Femal | 1998 |
Suppression of HHV-8 viremia by foscarnet in an HIV-infected patient with Kaposi's sarcoma and HHV-8 associated hemophagocytic syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; DNA, Viral; Foscarnet; Herpesvirus 8 | 1998 |
Cytomegalovirus retinitis and viral resistance: 3. Culture results. CMV Retinitis and Viral Resistance Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Baltimore; Blood; Cidofovir; Cytomeg | 1998 |
Expression of the late cytomegalovirus (CMV) pp150 transcript in leukocytes of AIDS patients is associated with a high viral DNA load in leukocytes and presence of CMV DNA in plasma.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 1999 |
Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antigens, Viral; Antiviral Agents; Cause of Death; | 2001 |
Strategies for management of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation: the "doubling of baseline CMV pp65 antigenemia" and the "cidofovir as rescue treatment approaches.
Topics: Antigens, Viral; Antiviral Agents; Bone Marrow Transplantation; Child; Cidofovir; Cytomegalovirus; C | 2001 |
Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
Topics: Adult; Antiviral Agents; Cidofovir; Cyclosporine; Cytomegalovirus; Cytomegalovirus Infections; Cytos | 2001 |